ALT Q4 2022 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$353M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

-$110,000-103.4% YoY

Gross Profit

-$19M17535.5% margin

Operating Income

-$23M20994.5% margin

Net Income

-$22M19690.9% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

-5600.0%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$207M

Total Liabilities

$22M

Stockholders' Equity

$185M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$110,000	$3M	-103.4%
Gross Profit	-$19M	-$18M	-8.6%
Operating Income	-$23M	-$24M	+3.7%
Net Income	-$22M	-$24M	+9.3%